Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $70.85 million. The enterprise value is -$17.15 million.

Market Cap	70.85M
Enterprise Value	-17.15M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, before market open.

Earnings Date	May 9, 2024
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 61.61 million shares outstanding. The number of shares has increased by 0.58% in one year.

Shares Outstanding	61.61M
Shares Change (YoY)	+0.58%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.32%
Owned by Institutions (%)	55.75%
Float	37.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.64
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.22, with a Debt / Equity ratio of 0.24.

Current Ratio	7.22
Quick Ratio	n/a
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -73.10% and return on invested capital (ROIC) is -74.19%.

Return on Equity (ROE)	-73.10%
Return on Assets (ROA)	-56.20%
Return on Capital (ROIC)	-74.19%
Revenue Per Employee	n/a
Profits Per Employee	-$1.76M
Employee Count	58
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.65% in the last 52 weeks. The beta is 1.30, so Passage Bio's price volatility has been higher than the market average.

Beta (1Y)	1.30
52-Week Price Change	+11.65%
50-Day Moving Average	1.36
200-Day Moving Average	0.93
Relative Strength Index (RSI)	39.35
Average Volume (30 Days)	357,125

Short Selling Information

The latest short interest is 1.32 million, so 2.15% of the outstanding shares have been sold short.

Short Interest	1.32M
Short Previous Month	1.21M
Short % of Shares Out	2.15%
Short % of Float	3.53%
Short Ratio (days to cover)	2.16

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-102.06M
Pretax Income	-102.06M
Net Income	-102.06M
EBITDA	-98.34M
EBIT	-102.06M
Earnings Per Share (EPS)	-$1.86

Full Income Statement

Balance Sheet

The company has $114.29 million in cash and $26.29 million in debt, giving a net cash position of $88.00 million or $1.43 per share.

Cash & Cash Equivalents	114.29M
Total Debt	26.29M
Net Cash	88.00M
Net Cash Per Share	$1.43
Equity / Book Value	111.28M
Book Value Per Share	1.81
Working Capital	101.62M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$78.26 million and capital expenditures -$146,000, giving a free cash flow of -$78.41 million.

Operating Cash Flow	-78.26M
Capital Expenditures	-146,000
Free Cash Flow	-78.41M
FCF Per Share	-$1.43

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.58%
Shareholder Yield	-0.58%
Earnings Yield	-144.05%
FCF Yield	-110.66%

Analyst Forecast

The average price target for Passage Bio is $9.33, which is 711.30% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.33
Price Target Difference	711.30%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2